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Age-related changes in cellular metabolism can affect brain homeostasis, creating conditions
that are permissive to the onset and progression of neurodegenerative disorders such as
Alzheimer’s and Parkinson’s diseases. Although the roles of metabolites have been exten-
sively studied with regard to cellular signaling pathways, their effects on protein aggregation
remain relatively unexplored. By computationally analysing the Human Metabolome Data-
base, we identified two endogenous metabolites, carnosine and kynurenic acid, that inhibit
the aggregation of the amyloid beta peptide (Aβ) and rescue a C. elegans model of Alzhei-
mer’s disease. We found that these metabolites act by triggering a cytosolic unfolded protein
response through the transcription factor HSF-1 and downstream chaperones HSP40/J-
proteins DNJ-12 and DNJ-19. These results help rationalise previous observations regarding
the possible anti-ageing benefits of these metabolites by providing a mechanism for their
action. Taken together, our findings provide a link between metabolite homeostasis and
protein homeostasis, which could inspire preventative interventions against neurodegen-
erative disorders.
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A lzheimer’s disease (AD) is a complex disorder character-ized by the presence of aberrant protein deposits in braintissues1–3. Although the molecular origins of this disease
are still to be firmly established, it is generally recognized that the
presence of protein deposits is associated with the dysregulation
of the protein homeostasis network4,5. In turn, this system is part
of a wider cellular homeostasis system, which includes a variety of
other components, including the metabolite homeostasis
system6,7.
Metabolites affect key steps in cellular pathways where they act
as substrates for enzymes or as signaling molecules for the acti-
vation of biochemical pathways. For example, caloric restriction
and intermittent fasting retard structural and functional decline
during aging in laboratory rodents and monkeys8–10. Moreover,
signaling pathways have evolved to respond to cellular stresses in
aging, with the AMPK and mTOR pathways being widely studied
in cellular development and ageing11–14. It is therefore important
to understand how neurodegenerative disorders associated with
aging, such as AD, are linked with aberrations in cellular
homeostasis. The specific hypothesis that we investigate here is
whether the dysregulation of metabolite levels is associated with
the aberrant aggregation of proteins in AD. We approach this by
testing if supplementing the dysregulated metabolites may pre-
vent or clear aggregation of misfolded proteins.
The impairment of various biological processes contributes to
the onset and progression of AD, including DNA repair,
inflammation, mitochondrial function, oxidative stress, neuronal
network excitability, metal ion homeostasis, autophagy, hypo-
thalamic regulation, adult neurogenesis, and protein homeostasis
(Fig. 1)1,15–28. Small molecule metabolites play key roles in these
biochemical processes, but it is still not known in detail which
among these roles are first dysregulated and are associated with
the pathophysiological onset and progression of the disease.
In this context, whether the phenomenon of protein misfolding
and aggregation is a cause or a consequence of the impairment in
these biological processes is yet to be firmly established. A wide
range of studies has indicated that protein aggregation can
directly result in activation of the downstream biochemical cas-
cades that significantly advance the pathology of AD29. The toxic
aggregate species are recognized to be Aβ and Tau oligomers,
whose abnormal interaction with cellular components can impair
neuronal functions29,30. Given our present understanding of AD,
slowing or inhibiting protein aggregation may contribute to
preventing the advancement of the disease. Thus, understanding
which pathways contribute towards this objective can offer
insightful windows of opportunity for preventative and ther-
apeutic interventions, as well as provide guidelines for sustainable
ways of living (e.g. lifestyle factors, exercise, and diet) that sup-
press AD and promote healthy aging.
In healthy organisms, protein aggregation is prevented by
specific branches of the protein homeostasis system, in particular
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Fig. 1 Metabolite homeostasis and protein homeostasis in Alzheimer’s disease (AD). a AD is associated with a wide range of dysfunctions in cellular
homeostasis (colored boxes). A variety of endogenous metabolites are involved in regulating these cellular processes (gray box insets). b Small molecule
endogenous metabolites can modulate the protein aggregation processes associated with the disease. By designing systematic studies we can uncover the
exact molecular mechanisms by which they balance protein homeostasis.
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and misfolding, and the unfolded protein responses (UPR) in the
endoplasmic reticulum and mitochondria31,32. Many heat shock
proteins from the HSR are molecular chaperones that guide the
conformation of proteins during biogenesis and prevent the
misfolding and aggregation that interfere with cellular function21.
Since the cytoplasm is also a pool of various metabolites produced
and shuttled across biochemical networks, it is expected that their
levels and threshold concentrations in the cell may have an effect
as small molecule regulators on the protein homeostasis network,
thus keeping aggregation-prone proteins in their soluble state.
Patel and colleagues showed that ATP enhances protein solu-
bility at physiological concentrations (mM range)33. One can thus
envisage that other endogenous metabolites may also contribute
to the modulation of protein aggregation.
Enhanced expression of molecular chaperones, which is pri-
marily regulated by the transcription factor heat shock factor 1
(HSF-1), has been shown to restore protein homeostasis in a
variety of protein misfolding disease models, suggesting that
this mechanism may represent a promising target for
preventative and therapeutic approaches34. Calamini et al. iden-
tified new classes of small-molecule protein homeostasis reg-
ulators that induce HSF1-dependent chaperone expression and
restore protein folding in multiple protein conformational
disease models. These beneficial effects on proteome stability are
mediated by HSF1, FOXO, NRF2, and the chaperone
machinery34. In fact, endogenous metabolites are also small
molecules that regulate key biological processes. Since the levels
of these metabolites can change in response to environmental
cues, it is important to understand their direct effects on protein
homeostasis.
In this work, we asked whether or not endogenous metabolites
can influence the aggregation of proteins, and if they do, what is
their mechanism of action. Is it a direct influence by binding to
the monomeric, oligomeric and fibrillar species or aggregates, or
is it indirect by acting on various other cellular homeostatic
mechanisms? Through our investigations, we identified two
human endogenous metabolites that trigger a cytoplasmic
unfolded protein response by increasing the levels of HSF-1, and
downstream HSP40 co-chaperones J-proteins, ultimately result-
ing in the clearance of Aβ aggregates in a C. elegans model of AD.
Results
Identification of endogenous metabolites as small molecule
protein homeostasis regulators. In order to identify metabolites
associated with AD, we started by calculating fragments and
similarity scores35 (see the “Methods“ section) of the small
molecules reported as protein homeostasis regulators by Cala-
mini et al.34 (Fig. 2a). Using these fragments, we screened the
Human Metabolome Database (HMDB)36 for metabolites
detected in the cerebrospinal fluid (CSF). As it is in direct
contact with the extracellular space of the brain, the CSF pro-
vides a window on brain metabolism by reflecting the bio-
chemistry of the brain37 in the form of its associated
metabolites. In this work, we only considered endogenous
metabolites, as we wanted to look into molecules active in
primary cellular mechanisms, not involving exogenous meta-
bolic products. Our reasoning is that focussing on endogenous
metabolites can help identify fundamental cellular processes
that are compromised in neurodegeneration as a response to
the environment and/or cellular insults.
Since the detection and quantification of metabolites in body
fluids is challenging, we filtered only those metabolites that were
extensively detected and quantified. We then used the KEGG
database38 to identify biochemical pathways associated with these
metabolites, and further, the metabolites that are particularly
dysregulated in neurodegeneration (Supplementary Data 1). In
the case of dysregulation, the levels of upregulation and
downregulation of these metabolites are available from the
HMDB and associated literature available therein. We then
performed a literature search to corroborate the dysregulated
status of the metabolites in neurodegeneration. We ranked this
status as an association score, by performing a PubMed search
(see the “Methods” section) (Supplementary Data 1). In principle,
the association score describes the association of AD with the
identified endogenous metabolite across studies reported in
PubMed. Classifying the identified metabolites into upregulated
and downregulated gives an insight into the effects of their
normal concentrations on maintaining cellular homeostasis and
their dysregulation in disease.
We found 186 of the 380 endogenous CSF metabolites to be
dysregulated in neurodegeneration (Supplementary Data 1). We
then focused on six of these metabolites: 1-methylhistidine,
homovanillic acid, melatonin, L-carnosine, vanylglycol, and
kynurenic acid (Table 1), which were selected because they
shared overlapping fragments with known HSF-1 protein home-
ostasis regulators (Fig. 2b). We then investigated experimentally
their possible roles in modulating the aggregation of Aβ42, the
highly cytotoxic 42-residue form of Aβ.
Carnosine and kynurenic acid rescue a C. elegansmodel of AD.
C. elegans is a well-characterized model of aging sharing funda-
mental biochemical similarities with humans. Moreover, with an
average lifespan of 2–3 weeks, it makes for a powerful in vivo tool
for studying protein aggregation. Since we are investigating
endogenous metabolites and wanted to investigate if and by
which mechanism metabolites can clear aggregates, we con-
sidered selecting the C. elegans in vivo system for screening
instead of an in vitro screening approach. We first carried out a
dose-dependent screening (0, 1, 5, and 10 μM) (extended data in
Supplementary Figs. 1 and 2) of the six metabolites that we
identified as proteostasis regulators to test the overall fitness of a
well-established C. elegans model, GMC101 (GMC), in which
Aβ42 is overexpressed in the large muscle cells39. This model
shows age-dependent inclusion formation and related toxicity,
which can be measured by a decrease in the number of body
bends per minute (BPM), an increase in paralysis rate, and a
decrease in the speed of movement39 (Fig. 3). We report any
significant benefits upon metabolite treatment as changes in
overall fitness, where we consider fitness as the total behavioral
response of worms as a function of BPM, speed (mm/s), and live
ratio. We used Thioflavin-T (ThT) as a positive control which has
been previously shown to profoundly extend lifespan and slow
aging in adult C. elegans40; these beneficial effects of ThT depend
on HSF-1, the stress resistance and longevity transcription factor
SKN-1, molecular chaperones, autophagy, and proteasomal
functions40 (Supplementary Figs. 1 and 2).
GMC and wild-type N2 worms were shifted onto the
metabolites at the L4 stage, in order to avoid developmental
effects, and subjected to motility assays on day 5 of adulthood,
when the phenotypic manifestations of Aβ42 toxicity are
prominent (Fig. 3). We found that three metabolites, carnosine,
vanylglycol and kynurenic acid, improved the worm fitness as
compared with the untreated GMC worms (Supplementary
Figs. 1, 2, and for detailed characterization refer Fig. 3). We used
ThT as a positive control for worm fitness40. We found that the
results obtained with carnosine and kynurenic acid were highly
reproducible in terms of enhanced motility and markedly
decreased NIAD-4-stained aggregates as compared to the
untreated worms, and thus selected these two metabolites for
further characterization.
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At different doses of metabolites, both carnosine and
kynurenic acid show a clear response in improvement of
motility at day 5 (Fig. 3b–e) as compared with the initial
(younger) days of adulthood. The GMC motility (in BPM) was
highest at a concentration of 15 μM carnosine and 10 μM
kynurenic acid, with a corresponding lower count of aggregates
(Fig. 3f, g). We saw that carnosine is equally effective in the
concentration range 10–25 μM, and. kynurenic acid was most
effective in lowering aggregate number at a 15 μM concentra-
tion. In both cases, further increase in concentrations (≥50 μM)
did not show any improvement in motility, possibly because of
unrelated toxic effects of the metabolites in C. elegans
(Supplementary Fig. 1h, i). We did not observe any overt
effects of carnosine and kynurenic acid on changes in worm
motility and total fitness score in wild-type N2 worms
(Supplementary Fig. 4). Total fitness score is calculated using
metrics that include body bends, speed, paralysis rates, area per
animal, and mean errors. The resulting fingerprint is generated
in the form of a radar chart using the open-source software as
described in Perni et al.41.
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Fig. 2 Identification of endogenous metabolites as protein homeostasis regulators that are dysregulated in AD. a Schematic of the computational
fragment-based strategy that we used to identify endogenous metabolites from the Human Metabolome Database (HMDB) as candidate protein
homeostasis regulators that are also dysregulated in AD. b Using this approach, we identified six candidate metabolites that serve as protein homeostasis
regulators (Table 1, Supplementary Fig. 1 and Supplementary Data 1).
Table 1 Dysregulated levels of six endogenous metabolites that we identified as protein homeostasis regulators in this study, as
reported in the literature (PubMed ID) and HMDB.
Endogenous metabolite Regulation Human Metabolome Database Reference/PubMed ID
1-methylhistidine Upregulated, Downregulated HMDB0000001
Homovanillic acid Downregulated HMDB0000118
Melatonin Downregulated HMDB0001389; 15725334, 14671188, 9920102, 12887656
Vanylglycol Downregulated HMDB0001490; 9880039
L-carnosine Downregulated HMDB0000033, HMDB0000745; 17031479, 17522447
Kynurenic acid Upregulated, Downregulated HMDB0000715; 31376341, 32276479, 17023091, 24855376
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Carnosine and kynurenic acid do not directly inhibit Aβ42
aggregation. To test whether carnosine or kynurenic acid could
directly inhibit Aβ42 aggregation, we carried out a ThT
fluorescence-binding chemical kinetics assay (see the “Methods”
section). We did not observe, however, any direct effects of these
two metabolites on the aggregation of Aβ42, at least over the
relatively wide range of concentrations that we tested (Fig. 4 and
Supplementary Fig. 3), which include physiologically relevant
ones, indicating that another mechanism should be present that
acts to clear the aggregates. Since the presence of this mechanism
does not exclude the possibility that other endogenous metabo-
lites may have a direct effect on Aβ42 aggregation, possibly by






























3 4 5 56 7
Carnosine (  M)
b


































































































Kynurenic acid treated GMC
Carnosine 
(i) Motility assay






























































































































COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02218-7 ARTICLE
COMMUNICATIONS BIOLOGY |           (2021) 4:843 | https://doi.org/10.1038/s42003-021-02218-7 | www.nature.com/commsbio 5
forming aggregates themselves or promoting phase separation of
Aβ42 within the cytoplasm, we propose that it will be very
interesting to test other endogenous metabolites for such a direct
effect on protein aggregation.
Carnosine and kynurenic acid increase levels of HSF-1 and
molecular chaperones. We then investigated the effects of car-
nosine and kynurenic acid on the expression of HSF-1, the master
regulator of the HSR in C. elegans. HSF-1 upregulates heat shock
protein genes that act as molecular chaperones to maintain
normal protein conformation under cellular stress, refold mis-
folded proteins, and target irreversibly damaged proteins for
degradation42–44 (Fig. 5 and Supplementary Fig. 5).
We used an antibody validated to identify C. elegans HSF-1 by
immunoprecipitation and mass spectrometry45, to probe for
HSF-1 in lysates from worms treated with carnosine or
kynurenic acid. We observed increased levels of HSF-1 following
treatment with both the metabolites (Fig. 5a). Levels of HSF-1
increased in a dose-dependent manner in response to both
carnosine and kynurenic acid treatment (Fig. 5a). In the C.
elegans lysate treated with the two metabolites, we observed the
HSF-1 band at ∼100 kDa.
HSF-1 primarily regulates the expression of genes encoding
molecular chaperones, particularly the heat shock proteins
HSP90, HSP70, and HSP40 that act as a cochaperone for
HSP7046–48. We looked at the levels of core HSF-1-regulated
chaperones and found that HSP90 and HSP70 levels were
elevated in the GMC worms treated with 15 μM kynurenic
acid, but not 15 μM carnosine as compared with untreated
GMC and wild-type worms (Fig. 5b, c). Both DNJ-12 and
DNJ-19 showed elevated levels in response to treatment with
carnosine and kynurenic acid as compared to untreated GMC
worms and treated wild-type N2 worms (Fig. 5d, e). In
contrast, we did not observe significant changes in the levels of
DNJ-13 upon metabolite treatment (Fig. 5f). DNJ-12 and
DNJ-19 are class A J-protein (HSP40) cochaperones that have
been characterized in vivo and in vitro for their protein
disaggregase functions that promote organismal health48. J-
proteins have also been previously characterized to have a
disaggregase activity in a C. elegans polyQ model, where
complexed J-protein co-chaperones of class A (DNJ-12 and
DNJ-19) and B (DNJ-13) enable disaggregase activity through
associations with HSP-110 and HSP-70, both individually and
in a synergistic cooperation48,49. Our data suggest that an
increase in HSF-1 levels upon treatment with carnosine and
Fig. 3 Carnosine and kynurenic acid prevent Aβ42 toxicity in a C. elegans model of AD (GMC). In vivo screening strategy to identify endogenous
metabolites that inhibit Aβ42 aggregation is illustrated in (a). We screened six identified candidate metabolites in a C. elegans model of Alzheimer’s
disease. Metabolites (depicted as M) were fed at the L4 stage of GMC worms and their effects were assessed at day 5 of adulthood through a (i) motility
assay that determines the overall fitness of the worms, in terms of changes in motility, quantified as body bends per minute (BPM) and (ii) quantification of
NIAD-4-stained Aβ42 aggregates (screening data shown in Supplementary Fig. 1). Panels b–g show characterization of kynurenic acid and carnosine to
rescue a C. elegans model of AD. Panels (b and c) show the motility of worms, measured in body bends per minute (BPM) on Y-axis vs. days of adulthood
on X-axis, treated with increasing concentrations of carnosine (blue) and kynurenic acid (red) compared to untreated worms (black). Increased thrashing
frequency was observed across the lifespan of the worm up to 15 µM of carnosine and kynurenic acid (b and c). The motility at day 5 of adulthood, where
phenotypic manifestations of Aβ42 are prominent in the GMC worm, is significantly improved by increasing carnosine up to 15 µM and for kynurenic acid
at 10 µM (d and e). The radar chart shows the overall fitness of C. elegans as a function of speed, bends per minute (BPM) and the live ratio as is seen on
each of its axis (d and e). Aggregate staining was quantified after worms were incubated with the amyloidogenic-specific dye NIAD-4 (f–g) (scale bar, 80
μm). White arrows in the panels (f–g) point to NIAD-4-stained Aβ42 aggregates, which appear orange-red in color. At all concentrations tested, carnosine
treatment significantly inhibited Aβ42 aggregation compared to the GMC worms as shown in (f). N2 control worms, which do not express Aβ42, are
shown for comparison (scale bar, 80 μm). Similar to carnosine, the aggregation of Aβ42 was inhibited by kynurenic acid treatment as shown in (g). For
NIAD-4 screening of aggregates, approximately 15–23 animals were analyzed per condition for GMC (AD) worms and ∼10 animals per control (N2)
worms. The beneficial effects of kynurenic acid and carnosine were observed in n= 3 biologically independent experiments. All error bars represent the
standard error of the mean (SEM). Statistics were performed using one-way ANOVA, Dunnett’s multiple comparisons against the untreated Aβ42 group
using GraphPad Prism, p-values are indicated on the plots.
Fig. 4 Carnosine and kynurenic acid do not have direct effects on Aβ42 aggregation. Kinetic profiles of the aggregation of a 2 μM Aβ42 sample in the
absence (black) and the presence of increasing concentrations of carnosine or kynurenic acid (represented in different colors). The aggregation process of
Aβ42 is not significantly accelerated or retarded by the presence of either of the metabolites (higher concentrations of the metabolites 20, 50, 100, and
500 μM are shown in Supplementary Fig. 3). Error bars are expressed as the standard deviations from three technical replicates.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02218-7
6 COMMUNICATIONS BIOLOGY |           (2021) 4:843 | https://doi.org/10.1038/s42003-021-02218-7 | www.nature.com/commsbio
kynurenic acid promotes increased levels of molecular
chaperones and cochaperones, in particular DNJ-12 and
DNJ-19 to clear Aβ42 aggregates.
We then asked whether the changes in protein levels were due
to altered transcription by performing real-time quantitative PCR
(RTqPCR). No significant fold changes in the mRNA levels of hsf-
1, daf-21, and hsp-70 were observed following treatment with
either metabolite. However, consistent with our protein data, we
observed that the mRNA levels of dnj-12 and dnj-19 were
elevated by treatment with both metabolites. Intriguingly, the
mRNA levels for dnj-13 were also elevated in carnosine, but not
kynurenic acid, treated worms, despite the fact that no significant
changes were observed at the protein level (Fig. 6a).
We further asked if these metabolites triggered UPR related to
the ER (UPRER) or mitochondria (UPRmt) by probing for mRNA
levels of hsp-4 and hsp-6, the canonical markers of the UPRER and
UPRmt, respectively50,51. There were no significant changes in
these two markers compared with the controls (Fig. 6b), thus
excluding these responses as underlying mechanisms for
clearance of aggregates in this study.
To determine whether carnosine and kynurenic acid treatment
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increased levels of molecular chaperones, we used RNA
interference (RNAi) to knockdown specific genes and asked
whether this abrogated the effects of carnosine or kynurenic acid
on Aβ42 aggregation and toxicity. If HSF-1 is playing a role in the
clearance of Aβ42 aggregates, then HSF-1 knockdown would
show an obvious aggregate-positive phenotype, with heightened
worm paralysis. Indeed, this was the case when we performed
RNAi against hsf-1 (see the “Methods” section) and treated the
GMC worms with water, carnosine, and kynurenic acid (Fig. 7).
In an empty vector L4440, we see that both carnosine and
kynurenic acid clear Aβ42 aggregates and increase overall fitness
when compared with the RNAi worms where hsf-1 is knocked
down prior to treatment with the two metabolites (Fig. 7a). In
these GMC hsf-1 knockdown worms, we see a higher number of
Aβ42 aggregates (Fig. 7b, c), together with a decrease in overall
fitness (Fig. 7a), even when supplemented with the metabolites.
Thus, overall, we see that the beneficial effects of carnosine and
kynurenic acid were markedly reduced after knocking down hsf-1
using RNAi (Fig. 7a). Note that the wild-type N2 worms, both
treated and untreated, showed no overt differences in overall
paralysis on hsf-1 knockdown (Fig. 7a radar plot and bar plots
N2). Previous studies have shown that the complete effect of
RNAi can take over 48 h to establish a significant knockdown
phenotype52,53, hence at day 5, our results are in agreement. As a
further study, it will be interesting to explore the effect of these
metabolites on the time course of ageing in healthy worms.
Next, we individually knocked down the genes daf-21 (HSP90),
hsp-1 (HSP70), dnj-13, dnj-12, dnj-19, and hsp-110 using RNAi to
study the consequent effects on C. elegans motility after treatment
with kynurenic acid. DNAJ (HSP40) interacts with HSP70 to
Fig. 5 Carnosine and kynurenic acid activate a cytosolic unfolded protein response through an HSF-1-dependent mechanism. Western blots show a
differential increase in protein levels on treatment with the two metabolites (a–f). On treatment with carnosine and kynurenic acid, we observe a relative
increase in the protein levels of molecular chaperones and their co-chaperones in worm lysates relative to the controls, untreated N2 and GMC. n=∼3000
worms per condition; we measured 3–4 replicates per condition; only a representative western blot is shown for each condition. From the experiments
described in Fig. 3, a significant increase in motility and a corresponding decrease in the NIAD-4-stained aggregates were observed at a dose of 15 μM of
both the metabolites. All error bars depict standard error of mean (SEM). a–f show bands of HSF-1, downstream molecular chaperones, and J proteins
namely HSP-90, HSP-70, DNJ-12, DNJ-19, and DNJ-13, respectively, for both N2 (wild type) and GMC (AD model) worms. For each Western blot
experiment, we used Tubulin signal to normalize for total protein concentration in each lane. We then normalized each condition of the chaperone/co-
chaperone band with its corresponding tubulin band from the same experiment run on a parallel gel, to plot the intensities in ImageJ. The gels for each
condition were run, respectively, at the same time, using the same running buffer, in the same electrophoretic cell and the same western blot transfer
sandwich onto membranes. These membranes were further developed using appropriate antibodies (see the “Methods“ section, Supplementary Fig. 5).
Statistics are performed in GraphPad Prism using ordinary one-way ANOVA; we used Dunnett’s multiple comparisons test with untreated (H2O) for each
N2 and GMC metabolite-treated groups; p-values are indicated in the figure sub-panels.
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Fig. 6 RTqPCR shows that carnosine and kynurenic acid activate a cytosolic unfolded protein response by elevating the transcript levels of the J-
proteins dnj-12 and dnj-19 in day 5 GMC worms. GMC worms were administered 15 μM each of carnosine and kynurenic acid and their mRNA levels
monitored by RTqPCR. a We did not observe any significant changes in the mRNA levels of hsf-1, hsp-90, and hsp-70. Carnosine treatment significantly
elevated transcript levels of class A and B J-proteins, DNJ-12, DNJ-13, and DNJ-19. Kynurenic acid, however, elevated the levels only of class A J-proteins,
DNJ-12, and DNJ-19. The changes in the transcript levels of J-proteins correlate to the protein level changes and are also supported by our RNAi
knockdown experiments, where DNJ-13 does not show a role in clearing out the aggregates of Aβ42 aggregates (Fig. 8a, b). b We also tested for any
changes in the UPRER and UPRmt after giving carnosine and kynurenic acid, however, found no significant changes in the markers, hsp-4 and hsp-6,
corresponding to the activation of these pathways, respectively. All data represent four biological replicates of day 5 C. elegans GMC. Y-axis represents
condition/GEOMEAN where condition refers to each hsf-1, daf-21, hsp-70, dnj-12, dnj-13, dnj-19, hsp-4, and hsp-6, and GEOMEAN is the geometric mean of
two housekeeping genes rpb-2 and cdc-42 for normalization. We performed statistics using GraphPad Prism using one-way ANOVA with Tukey pairwise
comparison of columns against the untreated GMC (AD) worms for each condition treated with metabolites. All error bars represent standard error of
mean (SEM). Significance p-values are indicated above the bar plot. ns indicates statistically non-significant.
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promote refolding and HSP110 to promote disaggregation.
Therefore, we also considered HSP110 in our RNAi study to
check for overall behavioral effects and Aβ42 aggregation in C.
elegans. We observed increased Aβ42 aggregates in each knock-
down GMC group that was otherwise suppressed by treatment
with kynurenic acid (Fig. 8a, b). Although we observed no
significant effects in each knockdown condition (Fig. 8c) at day 5
of adulthood after kynurenic acid treatment, there was a
significant increase in overall fitness in the empty vector L4440
upon kynurenic acid treatment as compared with the
Day 5 AD (GMC) Day 5 Control (N2)
C. elegans overall fitness (motility) assay
NIAD-4 Quantification 
Control - N2
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Fig. 7 Carnosine and kynurenic acid protect against Aβ42 aggregation and toxicity in an HSF-1-dependent manner. a RNAi knockdown of hsf-1 shows
decreased motility in GMC (AD) worms. L4440 is the empty vector control. On treatment with carnosine and kynurenic acid, a significant increase in
motility is observed in the L4440 phenotype as compared to a decrease in the hsf-1(RNAi) groups. The control N2 worms show no significant effect of the
metabolites carnosine (Car) and kynurenic acid (Kyn). The radar chart depicts overall fitness by comparing the three quantitative variables: worm speed
(mm/s), bends per minute and live ratio as is seen on its axis. The bar graph inset shows that RNAi knockdown of hsf-1 significantly impairs the beneficial
effects of carnosine and kynurenic acid. Statistics were performed using one-way ANOVA, Dunnett’s multiple comparisons test against the untreated
Aβ42 empty vector. ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05 (b). A corresponding decrease in NIAD-4 aggregates is observed in AD worms
treated with carnosine and kynurenic acid (Scale bars, 80 μm). For NIAD-4 staining, approximately 11–30 animals were analyzed per condition. All error
bars represent SEM. Statistics were performed using one-way ANOVA Dunnett’s multiple comparisons test against the untreated Aβ42 empty vector.
****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05. c Representative images of Aβ42 plaques show a significant clearance of aggregates in worms treated
with carnosine (Car) and kynurenic acid (Kyn). hsf-1 knockdown worms even when treated with carnosine and kynurenic acid did not clear aggregates.
White arrows point to NIAD-4-stained Aβ42 aggregates, which appear orange-red in color. For comparison, an empty RNAi vector L4440 GMC worm
head is shown.
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untreated GMC (AD) worms. This shows that kynurenic acid
indeed clears Aβ42 aggregates, which is mediated by these
chaperones, thus resulting in an improvement in the motility of
Aβ42-expressing worms.
Taken together, our data from western blots, RTqPCR, and
RNAi suggests that treatment with kynurenic acid and carnosine
elevates the levels of HSF-1 in a C. elegans model of AD, resulting
in transcriptional upregulation and thus increased levels of DNJ-
12 and DNJ-19 J-proteins. This then appears to cooperate with
and at least requires multiple core chaperones such as HSP70,
HSP90, and HSP110 to protect against Aβ42 aggregation and
associated toxicity in C. elegans (Fig. 8c).
Together, our data show how two metabolites trigger a
cytosolic unfolded protein response in a C. elegans model of
AD to clear Aβ42 aggregates and their associated toxicity. Since
levels of these metabolites may be age-related or disease-related,
we propose that metabolites can be inducers of protective quality
control cellular responses that protect against disease-associated
protein aggregation (Fig. 8c).
Discussion
We have shown how the protein homeostasis network, which
comprises several interdependent mechanisms including mole-
cular chaperones, detoxifying enzymes, and protein clearance
mechanisms54, can be modulated by endogenous metabolites. We
have reported a library of endogenous metabolites that can be
further explored for action on various cellular mechanisms
associated with protein homeostasis, and we characterized two
metabolites, carnosine and kynurenic acid, for their role in the
clearance of protein aggregates. These two metabolites are able to
inhibit Aβ42 aggregation in a C. elegans model of AD by trig-
gering a cytosolic unfolded protein response mediated through
HSF-1 and increased levels of the DNJ-12 and DNJ-19 J-proteins.
We anticipate that further studies will reveal how these meta-
bolites increase the levels of HSF-1 and thereby regulate its
function.
We propose a model for the restoration of protein homeostasis
by endogenous metabolites (Fig. 8c), where the two endogenous
metabolites regulate HSF-1 and downstream chaperones to clear
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Fig. 8 Kynurenic acid prevents Aβ42 toxicity in a C. elegans model of AD through the action of molecular chaperones. On treatment with 10 μM
kynurenic acid, a cytosolic unfolded protein response is activated by HSF-1 and involves HSP-90, HSP-70, HSP-110, HSP40 J proteins DNJ-12 and DNJ-19,
but not DNJ-13 (panels a–c). The overall fitness (bends per minute, speed and survival) in a C. elegans model of AD (GMC worms) is compromised even
after treatment with 10 μM kynurenic acid in the hsf-1, daf-21, hsp-70, hsp-110, dnj-12, dnj-13, and dnj-19 knockdowns as compared to the control L4440 (c). A
corresponding increase in NIAD-4 aggregates is observed (a and b). However, we do not see any aggregates on knocking down dnj-13, a class B J-protein,
suggesting it may not play a role in clearing out Aβ42 aggregates. The white arrows point to NIAD-4-stained Aβ42 aggregates, which appear orange-red in
color (scale bars, 80 μm). For motility assays n=∼260–1000 animals per condition, for NIAD-4 staining assay n= 11–29 for all conditions except
hsp110 knockdown, for which n= 4. All error bars represent SEM. a and c statistics were preformed using one-way ANOVA, Dunnett’s multiple comparisons
test against the control L4440 AD group treated with 10 μM kynurenic acid, ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05. d Schematic of the
mechanism by which the metabolites clear protein aggregates by mediating a heat shock response. We propose that metabolic dysregulation may thus be
a prior contributory factor to an imbalance in protein homeostasis.
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Aβ42 aggregates. With regard to clearance of aggregates, it is
plausible that (1) the aggregates are removed en masse by
autophagy, as autophagy has been linked to HSF-1 activity by
Kumsta and coworkers55, or (2) increased chaperones promote
the turnover of Aβ42 protein, thereby suppressing aggregate for-
mation. It cannot be that chaperones are just blocking aggregation
as we do not see a corresponding increase in soluble Aβ42 levels.
Carnosine is a dipeptide that occurs naturally in the brain,
kidney, and skeletal muscle of fish, birds, and mammals56. Post-
mitotic adult cells have higher carnosine concentrations than
actively dividing cells, although the reasons are not clear57,58;
carnosine synthesis is only associated with final stages of glial cell
maturation. It is also present only in post-mitotic retinal neurons
when energy metabolism switches from glycolysis to oxidative
phosphorylation56. Interestingly, carnosine has also been
observed to have a beneficial but unspecified organizational effect
towards mitochondria; its levels change with respect to energy
metabolism of the cell in ageing56. Taken together, these studies
suggest that carnosine has beneficial effects on cellular activity.
We see that in disease carnosine is downregulated (Table 1), and
our studies indicate that supplementation rescues AD disease
phenotype. Its subsequent metabolism on supplementation is a
problem underscored for future study. Elucidation of its
mechanism of action in the context of clearing protein aggregates,
therefore, is useful in exploiting its therapeutic potential.
Kynurenic acid is a tryptophan metabolite, which has anti-
inflammatory and immunosuppressive functions59,60, in addition
to acting as an antagonist affecting all ionotropic glutamate
receptors including NMDA, AMPA, and kainite receptors61.
Although kynurenic acid has been implicated to be neuropro-
tective in a vast majority of neurological conditions, its
mechanisms of action have not been fully clarified. Kynurenic
acid and associated metabolite levels are reported to be dysre-
gulated in people with sleep disorders62,63 and depression64
showing both upregulation and downregulation (Table 1). Sleep/
wake patterns have been reported to be disrupted in AD65.
Although depression has been associated as a risk factor for
developing AD, a genome-wide association study indicated no
significant genetic overlap between the two diseases66; interest-
ingly, the overlap could indeed be explained by a disruption of
neurotransmitter homeostasis67. Further, endurance exercise has
been reported to increase plasma levels of kynurenic
acid68 . Previously, kynurenine pathway has been suggested to be
a regulator of age-related protein toxicity69. In a C. elegans model,
van der Goot et al. show that depletion of tryptophan 2,3-diox-
ygenase (tdo-2), the first enzyme in the kynurenine pathway of
tryptophan degradation, increases tryptophan levels and sup-
presses toxicity of aggregation-prone proteins; moreover, they
show that feeding L-tryptophan also suppresses toxicity69. In
this study, we show a rescue of AD disease phenotype by
kynurenic acid supplementation; it is known that in C. elegans
and mammals, kynurenic acid is generated in spatially restricted
patterns in the nervous system, so we think that modifying its
levels endogenously, in a tissue-specific manner, will further give
insights into how its endogenous levels affect target proteins. Our
results on its mechanism of action on clearing protein aggregates
shed light on systematically exploiting its therapeutic potential.
Taken together, our results emphasize the need to explore in
more detail the effect of abnormal metabolite homeostasis in the
development of protein misfolding disorders.
Conclusions
The results that we have reported in this study support the view that
metabolite homeostasis and protein homeostasis are closely linked
and essential for overall cellular homeostasis. In particular,
metabolite homeostasis can be disrupted in an age-related manner
and may be associated with protein misfolding diseases. In general,
our results support the view that rebalancing cellular homeostasis
through the maintenance of metabolite homeostasis may offer
preventative approaches for neurodegenerative diseases.
Methods
Identification of endogenous metabolites in the HMDB. We used 200 molecules
as starting points, hereby referred to as seeds, from Calamini et al. 34 to calculate
fragments using a method reported by Joshi et al. 35. We screened the HMDB using
similarity and Tanimoto coefficients (>0.6) of the initial seeds. The hits obtained
were filtered if they satisfied the following conditions: endogenous, quantified and
detected, detected in the CSF. We further calculated if they were upregulated or
downregulated based on the normal vs. abnormal physiological concentrations
reported in the HMDB. This step was performed by literature search to assess their
association with disease, where we ranked the metabolites based on an association
score, which we operationally defined as the number of studies in which a meta-
bolite was reported as dysregulated in AD. To this end, we searched in PubMed
“Alzheimer’s disease AND metabolite”, where “metabolite” refers to each meta-
bolite in Supplementary Data 1.
Chemicals used in this study. All metabolites: kynurenic acid (K3375) carnosine
(C9625), melatonin (M5250), 1-methylhistidine (67520), homovanillic acid
(69673) were purchased from Sigma-Aldrich (Germany). Vanylglycol was pur-
chased from MolPort (MolPort-022-375-161). All metabolites were dissolved
in water.
Expression, purification, and preparation of Aβ42 peptide samples for kinetic
experiments. The recombinant Aβ42 peptide (MDAEFRHDSGYEVHHQKLVF-
FAEDVGSNKGA IIGLMVGGVVIA) was expressed in the Escherichia coli BL21
Gold (DE3) strain (Stratagene, CA, USA) and purified as described previously70.
Briefly, in the purification procedure, the E. coli cells were sonicated, and the
inclusion bodies were subsequently dissolved in 8M urea. A diethyl-aminoethyl
cellulose resin was then used to perform ion-exchange chromatography, and the
protein collected was lyophilized. These fractions were then further purified using a
Superdex 75 26/60 column (GE healthcare, IL, USA), and the fractions containing
the recombinant protein were combined, frozen, and lyophilized again. Solutions of
monomeric protein were prepared by dissolving the lyophilized Aβ42 peptide in 6
M GuHCl, and purified in 20 mM sodium phosphate buffer, 200 µM EDTA, pH 8.0
using a Superdex 75 10/300 column (GE Healthcare) at a flow rate of 0.5 ml/min.
ThT was added from a 2mM stock to give a final concentration of 20 µM. All
protein samples were obtained from the same single preparation and then pipetted
in low-binding Eppendorf tubes. Each sample was then pipetted into multiple wells
of a 96-well half-area, low-binding, clear bottom and PEG coating plate (Corning
3881), 80 µl per well, in the absence and the presence of different molar-equivalents
of carnosine or kynurenic acid, to give a final concentration of 1% DMSO (v/v).
The aggregation of Aβ42 (at 2 µM concentration70,71,72, was initiated by placing
the 96-well plate in a plate reader (Fluostar Omega or Fluostar Optima from BMG
Labtech, Aylesbury, UK) at 37 °C under quiescent conditions. The ThT
fluorescence was monitored in triplicate per sample as measured using bottom-
optics with 440 nm excitation and 480 nm emission filters. Kinetic traces were then
obtained for each well, and then processed to the fibrillar mass fraction by
normalizing the ThT fluorescence values at a given time t against the initial ThT
fluorescence value (which is taken as 0), and the final ThT fluorescence value at the
end of the reaction (which is taken as 1.0).
C. elegans experiments
Media. Standard conditions were used for the propagation of C. elegans73. Briefly,
animals were synchronized by hypochlorite bleaching, hatched overnight in M9 (3
g/l KH2PO4, 6 g/l Na2HPO4, 5 g/l NaCl, 1 µM MgSO4) buffer, and subsequently
cultured at 20 °C on nematode growth medium (NGM) (CaCl2 1 mM, MgSO4 1
mM, cholesterol 5 µg/ml, 250 µM KH2PO4 pH 6, Agar 17 g/l, NaCl 3 g/l, casein 7.5
g/l) plates seeded with the E. coli strain OP50. Saturated cultures of OP50 were
grown by inoculating 50 ml of LB medium (tryptone 10 g/l, NaCl 10 g/l, yeast
extract 5 g/l) with OP50 and incubating the culture for 16 h at 37 °C. NGM plates
were seeded with bacteria by adding 350 µl of saturated OP50 to each plate and
leaving the plates at 20 °C for 2–3 days. On day 3 after synchronization, the animals
were placed on NGM plates containing 5-fluoro-2′deoxy-uridine (FUDR) (75 µM)
to inhibit the growth of offspring and the temperature was raised to 24 °C.
Strains. All strains were acquired from the Caenorhabditis Genetics Center in
Minnesota, which is supported by NIH P40 OD010440. Two strains were utilized
for these experiments. The temperature sensitive human Aβ-expressing strain
dvIs100 [unc-54p::A-beta-1-42::unc-54 3′-UTR+mtl-2p::GFP] (GMC101) was
used, in which mtl-2p::GFP causes intestinal GFP expression and unc-54p::A-beta-
1-42 expresses the human full-length Aβ42 peptide in the muscle cells of the body
wall. Raising the temperature above 20 °C at the L4 or adult stage causes paralysis
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due to Aβ42 aggregation in the body wall muscle. The N2 strain was used for wild-
type worms.
Metabolite-coated plates. Aliquots of NGM media were autoclaved and poured and
seeded with 350 µl OP50 culture and grown overnight. After incubating for up to
3 days at room temperature, aliquots of L-carnosine (carnosine) or kynurenic acid
(or other metabolites) dissolved in water at different concentrations were added.
NGM plates containing FUDR (75 µM, unless stated otherwise) were seeded with
2.2 ml aliquots of compound dissolved in water at the appropriate concentration.
The plates were then placed in a laminar flow hood at room temperature to dry and
the worms were transferred to plates coated with metabolite at larval stage L4. The
six metabolites were initially screened in liquid media41. Carnosine was prepared at
room temperature to a stock concentration of 5 mM. Kynurenic acid was prepared
at 5 mM and compound dissolution was carried out at 100 °C. Stocks of the
compound were maintained at −20 °C until use and never thawed more than once.
Automated motility assay. At different ages, animals were washed off the plates
with M9 buffer and spread over an OP50 un-seeded 6 cm plate, after which their
movements were recorded at 20 fps using a recently developed microscopic pro-
cedure for 60–90 s41,74. Approximately 100–600 animals were counted per con-
dition at each indicated timepoint, unless otherwise specified for >600
(Supplementary Data 2). The automated motility tracker software avoids the
underestimation of errors resulting from worm collisions and overlap; it detects the
total number of worms, and also provides the upper limit on errors by considering
the maximum number of worms present in a single frame at the same time
(Supplementary Data 2)41.
NIAD-4 staining and imaging. NIAD-4 solution was prepared by dissolution in 100%
DMSO at 1mg/ml. Prior to worm incubation, a 1/1000 dilution in M9 was created.
After screening using the Wide-field Nematode Tracking Platform, ~300 worms per
condition were collected in M9 media and centrifuged at 20 °C at 2000 rpm for 2min
to a pellet. 1 ml of diluted NIAD-4 solution in M9 was then added to the pellet and
placed under gentle shaking (80 rpm) for 6 h. Worms were then transferred to
unseeded NGM plates and incubated at 20 °C for twelve hours. Worms were again
washed from the plates with M9 media, spun down, washed with 10ml M9, and
resuspended in 2ml M9. After gravity sedimentation, 15 µl worm solution was
spotted on 4% agarose pads. To anaesthetize the animals, 4 µl of 40mM NaN3 was
added, followed by a glass coverslip. Worms were imaged using a Zeiss Axio Observer
A1 fluorescence microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) with a
×20 objective and a 49004 ET-CY3/TRITC filter (Chroma Technology Corp, VT,
USA). An exposure time of 1000ms was employed. The nominal magnification was
×40 and images were captured using an Evolve 512 Delta EMCCD camera with a
high quantum efficiency (Photometrics, Tucson, AZ, USA). Approximately 11–30
animals were analyzed per condition, unless otherwise specified, and statistics were
performed using the one-way ANOVA against the untreated group. All statistics
herein were performed using GraphPad Prism. Quantification was performed using
ImageJ (NIH, MD, USA) to determine the grayscale intensity mean in the head of
each animal. The “fire” filter was used in ImageJ for visualization of NIAD-4-stained
aggregates. Total intensity (mean gray value) of the worm head was calculated by
outlining the worm head area from the nose to the pharynx. At day 5, the maximum
diameter of the worms across the head is 80 µm. Then the average (three readings
taken) background of the same area elsewhere on the image was calculated and
subtracted from the total mean gray value of the worm head. The resultant intensity,
after background subtraction, gives a readout of the NIAD-4 stained aggregates,
which appear orange-red and are marked with arrows in relevant figure panels.
Western blots. Approximately 3000 worms per condition were lysed in PBS. A
cocktail of protease inhibitor was added to the lysate (Sigma MS-SAFE Protease
and Phosphatase Inhibitor Cocktail). Anti-tubulin (Monoclonal anti-alpha-
Tubulin antibody produced in mouse, Sigma, T6074) was used for detection of
constitutively expressed tubulin for normalization of protein concentrations. HSF1
antibody was procured from Veena Prahlad (Iowa), HSP90 (rabbit anti-DAF-21)
from Patricia Van Oosten-Hawle (Leeds), HSP40 (anti-DNJ-12, DNJ-13, and DNJ-
19, all raised in rabbits) from Janine Kirstein (Berlin), HSP70 from John Labbadia
(UCL, London). Mouse and rabbit secondary antibodies were used (Alexa
Fluor 488-conjugated secondary antibodies). All quantifications were performed
using ImageJ software to determine the protein band intensity using densitometry.
3-4 technical replicates were used per condition and statistics were performed using
the two-way ANOVA against the untreated wild type (N2) and treated Aβ42
(GMC) worms groups. All statistics were performed using GraphPad Prism.
RNA interference. Bacteria harboring an empty vector (L4440) or a vector con-
taining hsf-1 dsRNA, were grown at 37 °C overnight in LB containing 100 μg/ml
ampicillin. Following overnight growth, cultures were induced with 5mM IPTG and
grown for a further 3 h at 37 °C. RNAi cultures were allowed to cool to room tem-
perature and then seeded onto NGM plates containing 100 μg/ml ampicillin and 1
mM IPTG. Bacterial lawns were then left to dry for 4 days on the bench. The control,
hsf-1 and downstream chaperone RNAi clones were obtained from the Ahringer RNAi
library and were sequence validated before use. Futhermore, these clones were shown
to knock-down their intended targets in the previous publications48,75,76.
RNA extractions, cDNA synthesis, and RTqPCR. Approximately 700, day 5 adult
worms, were resuspended in 250 μl Trizol and homogenized by vortexing three
times for 10 min continuously, with 20 min rest periods on ice between each round
of vortexing. Chloroform was added (1/5th volume) before samples were shaken
for 15 s by hand, and then centrifuged at 13,000×g for 15 min. The aqueous phase
was collected and mixed with an equal volume of 70% ethanol. RNA was then
purified using an RNeasy kit as per manufacturer’s instructions. cDNA was then
synthesized from 1 µg total RNA using iScript cDNA synthesis reagents (BioRad).
RTqPCR was performed using BioRad Advanced SYBR green master mix and a
BioRad CFX96 thermocycler using primers described in Table 2. The standard
curve method was used to quantify gene expression and relative-expression of
genes of interest was normalized to the house-keeping genes rpb-2 and cdc-42.
Statistics and reproducibility. The data presented as mean ± SEM were tested for
significance in the one-way ANOVA, using GraphPad Prism. Post-hoc compar-
isons were conducted using Dunnett’s multiple comparisons (Figs. 3, 5, 7, and 8)
and Tukey’s pairwise comparison (Fig. 6). For kinetic profiles of aggregation in
Fig. 4, error bars are represented from three technical replicates. Sample size: (a)
motility assays n= 100–600 worms, unless otherwise specified (b) western blots n
=∼3000 worms for each experimental replicate, (c) NIAD-4 aggregation assay n
= 11–30 animals per condition for GMC and n=∼10–12 animals per control
(N2), and (d) qPCR n= 4 biological replicates. All screenings, including RNAi,
were conducted under worm-motility tracker blinding to group identity, and then
matched. Significant results were marked according to critical p-values: ****p <
0.0001; ***p < 0.001; **p < 0.01; *p < 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data supporting the findings of this study are included in the main article and its
supplementary information files (Supplementary information, Supplementary Data 1 and
Supplementary Data 2). Raw data are also available from the corresponding author(s)
upon reasonable request.
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